WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Auto industry insiders highlight interdependence between China, EuropeLas Vegas Raiders take Georgia tight end Brock Bowers with the 13th pick in the NFL draftCharged in election interference cases, some are still in politicsChiefs trade up with Bills to select WR Xavier Worthy at No. 28 in NFL draftRavens pick Clemson CB Nate Wiggins in the first round, adding depth and speed to their secondaryThe 49ers take Florida receiver Ricky Pearsall with the 30th pick in the NFL draftSome Nikki Haley voters are hanging on to her candidacy and, like her, refuse to endorse TrumpLabour must match the Tories on defence spending, former Army chief warns Keir StarmerPackers take Arizona offensive tackle Jordan Morgan with 25th overall pick in NFL draftDriver charged with negligent homicide in fiery crash that shut down Connecticut highway bridge
2.6052s , 6497.6171875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Planet Pulse news portal